Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials

Philippe Huot; Woojin Kang; Esther Kim; Dominique Bédard; Sébastien Belliveau; Imane Frouni; Cynthia Kwan

doi:10.2217/nmt-2021-0051

Levodopa-induced dyskinesia: a brief review of the ongoing clinical trials

Neurodegener Dis Manag. 2022 Apr;12(2):51-55. doi: 10.2217/nmt-2021-0051. Epub 2021 Dec 23.

Authors

Philippe Huot^{1

2

3

4}, Woojin Kang¹, Esther Kim¹, Dominique Bédard¹, Sébastien Belliveau¹, Imane Frouni⁴, Cynthia Kwan¹

Affiliations

¹ Neurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, QC, H3A 2B4, Canada.
² Department of Neurology & Neurosurgery, McGill University, Montreal, QC, H3A 0G4, Canada.
³ Department of Neurosciences, Movement Disorder Clinic, Division of Neurology, McGill University Health Centre, Montreal, QC, H4A 3J1, Canada.
⁴ Département de Pharmacologie et Physiologie, Université de Montréal, Montreal, QC, H3C 3J7, Canada.

PMID: 34939425
DOI: 10.2217/nmt-2021-0051

No abstract available

Keywords: AV-101; HMG-CoA reductase inhibitors; JM-010; Parkinson's disease; Tianqi Pingchan; befiradol; dipraglurant; dyskinesia; eltoprazine; levodopa; mesdopetam.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Review

MeSH terms

Clinical Trials as Topic
Dyskinesia, Drug-Induced* / etiology
Humans
Levodopa* / adverse effects
Longitudinal Studies

Substances

Levodopa